COMMUNIQUÉS West-GlobeNewswire

Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease

12/02/2018 - 14:45

NEW YORK and CLEVELAND, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ: ABEO ), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life- [...]

Abattis awarded a Mitacs grant for R&D of nanoemulsified cannabinoid-rich hemp oil in conjunction with food scientists from the University of British Columbia

12/02/2018 - 14:31

VANCOUVER, British Columbia, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce the sponsorship of a research study in partnership with [...]

Dermira Showcases Commitment to Hyperhidrosis Education and Treatment at Leading Dermatology Conference

12/02/2018 - 14:30

MENLO PARK, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM ), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies [...]

Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association’s 12th Annual Scientific Meeting

12/02/2018 - 14:30

LAWRENCEVILLE, N.J., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation today announced that an abstract discussing the Company’s Phase III HEAT study evaluating ThermoDox® in combination with radiofrequency ablation [...]

AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD

12/02/2018 - 14:15

BROOKLYN, N.Y., Feb. 12, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal [...]

Rick Van Kirk, CEO of Pro-Dex, Inc. Returns to “Stock Day” with Everett Jolly

12/02/2018 - 14:12

PHOENIX, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Pro-Dex, Inc. (NASDAQ: PDEX ) (“Pro-Dex” the “Company”), CEO Rick Van Kirk joined Everett Jolly on “Stock Day” to review recent accomplishments and 2018 expectations. Pro-Dex [...]

Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid’s PS-Targeting Program Including Bavituximab

12/02/2018 - 14:05

TUSTIN, Calif. and BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO ) (NASDAQ: CDMOP ) (“Avid”) and Oncologie, Inc. today announced that the companies have entered into an Asset Assignment [...]

Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®

12/02/2018 - 14:03

Positive meeting with the FDA about the resubmission of an NDA for Firdapse Resubmission of NDA for Firdapse on schedule for end of the first quarter CORAL GABLES, Fla., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Catalyst [...]

Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis

12/02/2018 - 14:00

Results from REVERSE are intended to serve as the basis for seeking marketing approval of OCA for the treatment of NASH patients with compensated cirrhosis REGENERATE and REVERSE pivotal trials expand Intercept’s [...]

PotNetwork Holding Inc. Releases 2017 Financial Statements and Provides Further Update on Finalization of PCAOB Audit Process

12/02/2018 - 14:00

FORT LAUDERDALE, Fla., Feb. 12, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE--PotNetwork Holding Inc. (the “Company”) (OTC Pink:POTN) released today its unaudited financial statements for fiscal year 2017, which have been [...]

Key Strategies for Implementing Proteomics-Based Tests Across Disease States Highlighted in Current Opinion in Biotechnology

12/02/2018 - 14:00

SEATTLE and SALT LAKE CITY, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Sera Prognostics, a women’s health company, in collaboration with The Institute for Systems Biology and Integrated Diagnostics (Indi), today announced a [...]

Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder

12/02/2018 - 14:00

Company enters into license agreement with Strategic Science & Technologies, LLC to develop Topical Sildenafil, now in Phase 2 clinical studies SAN DIEGO, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. ( [...]

American Health Council Names Bernard Ogon, MD to Physician Board

12/02/2018 - 14:00

NEW YORK, Feb. 12, 2018 (GLOBE NEWSWIRE) -- The American Health Council has named Bernard Ogon, MD to its Physicians Board. An experienced Medicine Practitioner, Dr. Ogon founded the Tri-State Visiting Home Physicians [...]

Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting

12/02/2018 - 14:00

ROCKVILLE, Md., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, [...]

U.S. Patent and Trademark Office has granted to Todos Medical two additional patents

12/02/2018 - 14:00

REHOVOT, Israel, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Todos Medical, Ltd. Inc. (OTCQB:TOMDF) ( www.todosmedical.com ), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early [...]

Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

12/02/2018 - 14:00

Based on FDA Feedback, Opiant Intends to Pursue 505 (b)(2) Development Pathway Opiant Anticipates Submitting an NDA for this Product Candidate in 2020 SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Opiant [...]

India Globalization Capital’s CEO to Speak at CEO Healthcare Symposium in NY on February 12 & 13

12/02/2018 - 14:00

BETHESDA, Md., Feb. 12, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) announced today that Ram Mukunda will be a speaker at the upcoming CEO Healthcare Symposium in New York on February 12 [...]

Horizon Discovery Enters into License Agreement with US Immuno-Oncology Company

12/02/2018 - 13:00

Horizon Discovery Enters into License Agreement with US Immuno-Oncology Company Horizon out-licenses proprietary cell line and Helitron transposon gene editing technologies demonstrating Horizon's ability to generate [...]

Allergy Therapeutics: Completion of recruitment in PQ Grass Phase II trial

12/02/2018 - 13:00

Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Completion of recruitment in PQ Grass Phase II trial Trial running ahead of schedule with data now due in early H2 2018 12 February 2018 Allergy [...]